CAMP4 THERAPEUTICS CORP (CAMP)
Health Care · RNA therapeutics / antisense oligonucleotides for rare genetic diseases · NASDAQ
CAMP4 is pioneering a novel RNA-targeting platform to upregulate deficient genes in rare genetic diseases, starting with SYNGAP1-related developmental epilepsy.
What CAMP4 THERAPEUTICS CORP does
CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics designed to upregulate gene expression and restore healthy protein levels for treating genetic diseases. The company's lead product candidate, CMP-002, is an intrathecally delivered antisense oligonucleotide targeting SYNGAP1-related disorder, a rare developmental and epileptic encephalopathy. CAMP4's proprietary RAP Platform systematically identifies and characterizes regulatory RNAs (regRNAs) that control gene expression, enabling rapid development of novel ASO candidates to amplify target gene expression in specific tissues.
Themes: Gene upregulation / haploinsufficiency, Rare genetic diseases, Developmental and epileptic encephalopathy (DEE), Central nervous system (CNS) therapeutics, SYNGAP1-related disorder, RNA therapeutics / antisense oligonucleotides
Fundamentals
- Price$4.48 as of 2026-08-21 close
- Market cap$281M as of 2026-08-21
- 1-year return+181.8% 2025-08-21 close $1.59 → 2026-08-21 close $4.48
- P/En/a negative earnings
- Net margin-7.3% as of 2026-08-24
- Gross margin+35.8% as of 2026-08-24
- ROE-194.7% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+5.6% as of 2026-08-24
- Revenue CAGR (3y)+216.1% SEC XBRL
- Beta-24.96 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How CAMP compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CAMP4 THERAPEUTICS CORP looks technically
CAMP4 THERAPEUTICS CORP (CAMP) is trading 0.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 31 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 6 trading days ago. It is 42.2% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 0.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +0.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.11 | $4.11 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.46 | $4.46 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 28 calendar days ago — the swings before that are what the structure reading is measured on | 28 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 2.9. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 31 trading days ago — a "death cross", a bearish long-term signal | 31 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 0.4% above | +0.4% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with buyers in control | 34.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30) | 53.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($3.99 to $6.00) — its "stochastic" reading is 24 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 24.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 15 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.75 | $7.75 |
|---|---|---|
| From the 52-week high | it is 42.2% below its 52-week high (its highest price of the past year) | -42.2% |
| Above the 52-week low | it is 239.4% above its 52-week low (its lowest price of the past year) | +239.4% |
| Below the 52-week high | it is 42.2% below its highest point of the past year | 42.2% |
| Since a 20-day breakout | it made a new 20-day high about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day high about 6 trading days ago | 6 sessions |
| All-time high | its highest closing price on record is $12.30 (set on 2024-10-14) | $12.30 |
| Given back of the 52-week move | over the past year its closes ranged ($1.36 to $7.13), and it has given back around half of its rise from last year’s low — 46% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.38 to $3.56. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 45.9% |
| From the all-time high | it is 63.6% below its all-time high | -63.6% |
| Nearest price level | it is trading 2.8% below a resistance level at $4.61 — a price it turned at twice since 2024-12-20, most recently on 2025-11-07. Since 2024-10-11 it has 9 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.8% |
| All-time low | its lowest closing price on record is $1.30 (set on 2025-06-20) | $1.30 |
| Above the all-time low | it is 243.3% above its all-time low | +243.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 82% of the past ~6 months) | 82nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4569 between its high and its low — about 10.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4569 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.08 and $5.37 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.08 – $4.23 – $5.37 |
| Typical daily range (% of price) | its price moves about 10.2% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 10.2% |
| Stretch from the 200-day average | it is sitting essentially on its 200-day average price (0.4% above it in plain percentage terms) | at its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.57× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 5.8% since the prior reading | +5.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.9% |
|---|---|---|
| Open gap | it gapped 4.7% above the previous close 11 sessions ago and has not traded back through the level it left behind at 4.01 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.7% |
| Gap filled | a 5.7% gap up opened on 2026-08-17 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 38.1 percentage points (the stock gained 40.4% while the market gained 2.3%) | +38.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 1.3 percentage points (the stock gained 1.8% while the market gained 3.1%) | -1.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 7.8 percentage points (the stock gained 3.2% while the market gained 11.1%) | -7.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 161.3 percentage points (the stock gained 181.8% while the market gained 20.5%) | +161.3% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, MACD momentum is positive — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 2.1% of the share price. | 0.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 7% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.83 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | -7.2% |
|---|
Price levels it has turned at before
CAMP last closed at $4.48 on 2026-08-21. Since 2024-10-11 it has turned at 9 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.61 | Resistance | 2.8% above the last close | turned there twice · 2024-12-20 to 2025-11-07 |
| $3.99 | Support | 11.0% below the last close | turned there twice · 2025-03-11 to 2025-03-21 |
| $5.03 | Resistance | 12.3% above the last close | turned there three times · 2026-02-24 to 2026-05-13 |
| $3.89 | Support | 13.2% below the last close | turned there twice · 2026-03-03 to 2026-03-30 |
| $3.81 | Support | 14.8% below the last close | turned there twice · 2025-10-10 to 2026-05-05 |
| $5.21 | Resistance | 16.2% above the last close | turned there three times · 2025-02-18 to 2026-06-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $2.90.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Pulled back from the 12-month high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.29 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$9.08 range $6.50 – $15.00; median $8.50
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CAMP
- Consensus EPS estimate-$0.165 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Lead program CMP-002 is still in preclinical/early clinical development with no approved products yet; regulatory approval, clinical trial success, and commercialization remain uncertain","Dependence on third-party manufacturing partners to comply with significant manufacturing regulations; supply chain disruptions could delay development and commercialization","Reliance on intellectual property licensed from third parties; loss of licenses or inability to obtain future licenses on commercially reasonable terms could impair competitive position and product development"]
What changed in the latest 10-Q
AI-assisted comparison of CAMP's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 2025 Form 10-K filed March 5, 2026 (newer filing) vs. 2024 Form 10-K filed March 27, 2025 (older filing)
- Specific disease characterization: SYNGAP1 described as 'severe developmental and epileptic encephalopathy (DEE) characterized by seizures, developmental delays, and cognitive impairments' (newer)
- Updated patient population estimate: 'approximately 21,000 individuals living with SYNGAP1 in the United States and the five largest European markets' (newer)
- Statement about submitted Australian regulatory filing: 'We have submitted our first regulatory filing in Australia to enable initiation of a clinical trial in individuals with SYNGAP1, with additional global regulatory filings planned in 2026' (newer)
- Specific financial figures: net proceeds of $28.1 million from December 2025 underwritten offering, $46.7 million from September 2025 private placement, $72.4 million from IPO, $188.3 million from convertible preferred stock sales through March 31, 2026 (newer)
- $22.8 million in recognized research collaboration and license revenue through March 31, 2026 (newer)
- Specific net loss figures: '$18.3 million and $12.4 million for the three months ended March 31, 2026 and 2025' (newer)
- Accumulated deficit of $310.5 million as of March 31, 2026 (newer)
- Removed:
- Separate 'Overview' section header present in older filing, removed in newer filing
- Reference to CMP-001 (formerly CMP-CPS-001) for urea cycle disorders treatment entirely removed
- Details about Phase 1 clinical trial completion in healthy volunteers for CMP-001 removed
- Information about UCDs (urea cycle disorders) and CPS1 enzyme removed
- Details about Phase 1b expansion approval in the Netherlands removed
- Patient population estimate for OTC heterozygous females removed
- Detailed description of ammonia metabolism and urea cycle activity removed
- May 16, 2025 ASGCT Annual Meeting presentation reference removed
- Specific mention of 'GLP toxicology studies' status removed
- Reworded:
- Disease name: 'SYNGAP1-related disorders' (older) changed to 'SYNGAP1-related disorder, or SYNGAP1' with specific DEE characterization (newer)
- Patient population framing: broader epidemiological description in older filing condensed to specific geographic estimate in newer filing
- Clinical trial timeline: 'as early as the second half of 2026' (older) changed to 'in the second half of 2026' with 'Pending regulatory clearance' (newer)
- Product candidate naming: CMP-002 described without former name reference in newer filing (older filing included 'formerly known as CMP-SYNGAP-01')
- Regulatory pathway description shifted from completed GLP toxicology status to submitted Australian filing status
- Notes:
- Older filing text appears truncated at end of visible excerpt; comparison limited to complete sentences available
- Newer filing text also appears truncated at final paragraph; incomplete G&A cost discussion
Risk Factors
- Removed:
- Removed from newer filing (2026-05-07): reference to 'planned good laboratory practices toxicology studies' in the second bullet point about regulatory submissions
- Removed from newer filing (2026-05-07): phrase 'we may develop' after 'any product candidates' in third bullet point
- Removed from newer filing (2026-05-07): phrase 'we may develop' after 'any product candidates' in seventh bullet point
- Reworded:
- Newer filing (2026-05-07): 'the period during which the results of the trials are expected to become available' vs. Older filing (2025-11-06): 'the period during which the results of the trials are expected become available' - added 'to' before 'become'
- Newer filing (2026-05-07): 'or pandemic or epidemic disease outbreaks' vs. Older filing (2025-11-06): ', or pandemic or epidemic disease outbreaks' - removed comma before 'or' in the series
- Notes:
- The two filings contain the same forward-looking statements section with minor editorial changes; the content is substantially identical
- Page number references differ between filings (Item 1A Risk Factors on page 31 in newer vs. page 34 in older), reflecting different document lengths
- Text appears truncated at the end of both excerpts, limiting full comparison of the complete section
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CAMP — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding CAMP as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 5,536,703
- Reported value $24,416,860
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CAMP had 1,482,311 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CAMP had 2.36% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.37 days to cover at the same settlement.
- Reported short interest (shares) 1,482,311
- Short interest (% of shares outstanding) 2.36%
- Prior settlement (shares) 1,442,275
- Reported change 2.78%
- Days to cover (reported) 8.37
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Ionis Pharmaceuticals (IONS)
- Alnylam Pharmaceuticals (ALNY)
- Sarepta Therapeutics (SRPT)
- Biogen (BIIB)
- PTC Therapeutics (PTCT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CAMP vs…
CAMP ranks in…
Frequently asked questions
What does CAMP4 THERAPEUTICS CORP (CAMP) do?
CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics designed to upregulate gene expression and restore healthy protein levels for treating genetic diseases. The company's lead product candidate, CMP-002, is an intrathecally delivered antisense oligonucleotide targeting SYNGAP1-related disorder, a rare developmental and epileptic encephalopathy.
What sector is CAMP4 THERAPEUTICS CORP (CAMP) in?
CAMP4 THERAPEUTICS CORP (CAMP) is classified in the Health Care sector. Its industry is RNA therapeutics / antisense oligonucleotides for rare genetic diseases. It trades on NASDAQ.
Who are CAMP4 THERAPEUTICS CORP's (CAMP) competitors?
Notable peers of CAMP4 THERAPEUTICS CORP (CAMP) include Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sarepta Therapeutics, Biogen and PTC Therapeutics. This peer set is informational only — not financial advice.
Is CAMP4 THERAPEUTICS CORP (CAMP) overbought or oversold right now?
CAMP4 THERAPEUTICS CORP (CAMP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 53, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CAMP come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.